Government to back two companies’ drug development

Published: 2012-08-10 06:57:00

Updated: 2012-08-10 06:57:00

Daewoong Pharmaceutical plans to develop a combination drug for treatment of cardiovascular disease, and HanAll Biopharma will also carry out clinical trials for its sustained-release pulmonary hypertension drug with low molecular weight as part of a government program to cultivate blockbuster drugs, targeting the international market.

The Korea Drug Research Association (KDRA) has recently ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.